Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 15
2021 21
2022 22
2023 11
2024 8
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Sharma A, Gemmy Cheung CM, Arias-Barquet L, Ozdek S, Parachuri N, Kumar N, Hilely A, Zur D, Loewenstein A, Vella G, Bandello F, Querques G. Sharma A, et al. Among authors: parachuri n. Retina. 2022 Mar 1;42(3):e20-e22. doi: 10.1097/IAE.0000000000003366. Retina. 2022. PMID: 34861660 No abstract available.
Brolucizumab and immunogenicity.
Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, Loewenstein A. Sharma A, et al. Among authors: parachuri n. Eye (Lond). 2020 Oct;34(10):1726-1728. doi: 10.1038/s41433-020-0853-9. Epub 2020 Apr 6. Eye (Lond). 2020. PMID: 32251366 Free PMC article. No abstract available.
Brolucizumab in polypoidal choroidal vasculopathy.
Sharma A, Parachuri N, Kumar N, Kuppermann BD, Loewenstein A, Bandello F. Sharma A, et al. Among authors: parachuri n. Expert Opin Biol Ther. 2022 Jul;22(7):809-812. doi: 10.1080/14712598.2022.2094239. Epub 2022 Jun 27. Expert Opin Biol Ther. 2022. PMID: 35737884 No abstract available.
Immunogenicity: Clouding the Future of Intravitreal Therapy.
Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD. Sharma A, et al. Among authors: parachuri n. Ocul Immunol Inflamm. 2023 Nov;31(9):1746-1749. doi: 10.1080/09273948.2022.2139273. Epub 2022 Nov 4. Ocul Immunol Inflamm. 2023. PMID: 36332149 No abstract available.
Biosimilars for Retinal Diseases: An Update.
Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Sharma A, et al. Among authors: parachuri n. Am J Ophthalmol. 2021 Apr;224:36-42. doi: 10.1016/j.ajo.2020.11.017. Epub 2020 Dec 9. Am J Ophthalmol. 2021. PMID: 33309691 Review.
Approved biosimilar ranibizumab-a global update.
Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, Loewenstein A, Kuppermann BD. Sharma A, et al. Among authors: parachuri n. Eye (Lond). 2023 Feb;37(2):200-202. doi: 10.1038/s41433-022-02246-5. Epub 2022 Sep 16. Eye (Lond). 2023. PMID: 36114290 Free PMC article. No abstract available.
Biosimilar anti-VEGF-Yardsticks to ensure biosimilarity.
Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD. Sharma A, et al. Among authors: parachuri n. Eye (Lond). 2023 Jan;37(1):4-5. doi: 10.1038/s41433-022-02177-1. Epub 2022 Jul 14. Eye (Lond). 2023. PMID: 35835988 Free PMC article. No abstract available.
65 results